The Impact of SGLT1 Inhibition on Frailty and Sarcopenia: A Mediation Mendelian Randomization Study
Open Access
- 30 October 2024
- journal article
- research article
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 15 (6) , 2693-2704
Abstract
Background: Although pharmacological effects of SGLT2 inhibitors on the development of frailty and sarcopenia were known, the role of SGLT1 remained less clear. The present study investigated the possible effect of SGLT1 inhibition on these conditions and explored potential mediators.Methods: A two‐sample Mendelian randomization (MR) analysis was performed to assess the effect of SGLT1 inhibition on frailty index (FI) and low grip strength in individuals aged 60 years and older using both the FNIH and EWGSOP criteria. Subsequently, a two‐step MR analysis was conducted to investigate the mediating role of insulin resistance phenotype and identify potential mediators of the effect of SGLT1 inhibition on the FI and low grip strength from 1558 plasma proteins and 1352 metabolites.Results: Genetically predicted SGLT1 inhibition was associated with decreased FI (β: −0.290 [95% CI: −0.399, −0.181]) and reduced risk of low grip strength in individuals aged 60 years and older under both FNIH (β: −0.796 [95% CI: −1.216, −0.376]) and EWGSOP criteria (β: −0.287 [95% CI: −0.532, −0.041]). The two‐step MR analysis demonstrated the role of insulin resistance phenotype in mediating SGTL1 inhibition on alleviating frailty (mediation proportion = 19.56% [95% CI: 8.42%, 30.70%]). After screening, 24 proteins and 16 metabolites were identified as mediators of the impact of SGLT1 inhibition on FI. Additionally, 13 proteins and 16 metabolites were found to mediate the effect of SGLT1 inhibition on low grip strength according to FNIH criteria while 22 proteins and 6 metabolites were shown to mediate the impact of SGLT1 inhibition on low grip strength under EWGSOP criteria.Conclusions: SGLT1 inhibition potentially mitigated frailty and sarcopenia through several biological mediators, shedding new light for therapeutic intervention.Keywords
This publication has 95 references indexed in Scilit:
- Sodium–Glucose Cotransporter 2 Inhibitors Influence Skeletal Muscle Pathology in Patients with Heart Failure and Reduced Ejection FractionEuropean Journal of Heart Failure, 2024
- Role of sarcopenia in the frailty transitions in older adults: a population‐based cohort studyJournal of Cachexia, Sarcopenia and Muscle, 2022
- Physiological Systems in Promoting Frailty2022
- Pathogenesis of sarcopenia and the relationship with fat mass: descriptive reviewJournal of Cachexia, Sarcopenia and Muscle, 2022
- Associations between inflammatory markers, body composition, and physical function: the Copenhagen Sarcopenia StudyJournal of Cachexia, Sarcopenia and Muscle, 2021
- CPT1 regulates the proliferation of pulmonary artery smooth muscle cells through the AMPK-p53-p21 pathway in pulmonary arterial hypertensionMolecular and Cellular Biochemistry, 2018
- Development of SGLT1 and SGLT2 inhibitorsDiabetologia, 2018
- Acute and long‐term administration of palmitoylcarnitine induces muscle‐specific insulin resistance in miceBioFactors, 2017
- Frailty and Primary Sarcopenia: A Review2017
- Effect of aspartate, asparagine, and carnitine supplementation in the diet on metabolism of skeletal muscle during a moderate exercisePhysiology & Behavior, 1995